key: cord-1053365-19w2d3mg
authors: Gupta, Alpana K.; Nethan, Suzanne Tanya; Mehrotra, Ravi
title: Tobacco use as a well-recognized cause of severe COVID-19 manifestations
date: 2020-11-19
journal: Respir Med
DOI: 10.1016/j.rmed.2020.106233
sha: d611acd1d71ba39cbcb030f2c5756cb82bce30a8
doc_id: 1053365
cord_uid: 19w2d3mg

INTRODUCTION: The Coronavirus disease (COVID-19) infection is caused by the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) primarily affecting the lungs. All tobacco-related illnesses including asthma, chronic obstructive pulmonary disease (COPD), and coronary artery disease are known to reduce the lung capacity and impair the immune system of the body and can greatly influence the ability to fight the novel coronavirus. The purpose of this state-of-the-art literature review is to summarize the evidence of the association of tobacco use with the severity of the COVID-19 manifestations. METHOD: Articles describing the association of tobacco use with the severity of COVID-19 manifestations were searched on PubMed, MEDLINE, and Google. This review covers the relevant studies on the subject published from January 1, 2020 to September 10, 2020. RESULTS: Tobacco use in all forms, whether smoking or chewing, is significantly associated with severe COVID-19 outcomes. Pre-existing comorbidities in tobacco users such as cardiovascular diseases, diabetes, respiratory diseases and hypertension were found to further aggravate the disease manifestations making the treatment of such COVID-19 patients more challenging due to their rapid clinical deterioration. CONCLUSIONS: Current review indicates that nicotine exposure is linked to cardiopulmonary vulnerability to COVID-19 and tobacco use can be a potential risk factor for not only getting the viral infection but also its severe manifestations. The current pandemic provides a teachable moment to break the cycle of nicotine addiction and accelerate national tobacco control programs to achieve a tobacco-free world.

Tobacco is a prime cause of potentially preventable global morbidity and mortality, leading to about 8 60 million deaths in a year, mainly due to lung and heart diseases [1] . Low and middle-income countries 61 have 80% of the world's 1.3 billion tobacco users, many of whom are reeling under the heavy burden 62 of tobacco-related illness and death [2] . 71% of all lung cancer deaths and 42% of chronic obstructive 63 pulmonary disease (COPD) and 10% of cardiovascular disease are attributable to tobacco use [3] . 64 Tobacco products are found to contain about 4000 toxic chemicals with 36 known carcinogens [4,5].

exposed to cigarette smoke [27] . The radiological manifestation of COVID-19 is mainly peripheral ground-glass opacity while age, smoking and hypertension were used to predict the severity of COVID-19 infections begin at the ACE2 receptor, a neurotransmitter protein present on the surface of the cells and tissues in the lungs, heart, blood vessels, kidneys, liver, intestines, and epithelial cells in 151 the upper and lower respiratory tracts [40] . ACE2 is a critical mediator of the renin-angiotensin system 152 (RAS) signaling throughout the body and its dysfunction leads to critical congestive heart failure, 

There is a very close association between tobacco use and severe COVID-19 manifestations. As 258 nicotine exposure is linked to cardiopulmonary vulnerability to COVID-19, tobacco use could be a 259 potential risk factor for, not only contracting the viral infection but also making the treatment of such 260 COVID-19 patients more challenging. Hopefully, the COVID-19 pandemic could just prove to be the 261 game-changer and a teachable moment that we have been waiting for, to ultimately achieve a tobacco-262 free world. 

Tobacco use and vaping in the COVID 19 era

Change in tobacco and electronic 548 cigarette use and motivation to quit in response to COVID-19

The tobacco industry in the time of COVID-19: Time to shut it down?

COVID-19: Sounding the Alarm to Revisit National Tobacco Control 553

COVID-19 poses novel challenges for global primary care, Npj 556 Prim. Care Respir. Med. 30 (2020) 30

J o u r n a l P r e -p r o o f